Increased expression levels of αvβ6 are prognostic indicators of poor survival in patients with various types of tumors [79,82,84,85,86], and various ligands of this integrin coupled to tumor imaging agents are currently being tested in cancer patients for tumor imaging purposes [87,88,89,90,91]; thus, the development of CgA-derived peptides capable of recognizing this integrin in tumors is of great experimental and clinical interest. This evidence concerns the gene CGA and cancer.